PHIBRO ANIMAL HEALTH CORP-A (PAHC) Stock Fundamental Analysis
USA - NASDAQ:PAHC - US71742Q1067 - Common Stock
43.76 USD
+0.72 (+1.67%)
43.76 USD
0 (0%)
We assign a fundamental rating of 6 out of 10 to PAHC. PAHC was compared to 191 industry peers in the Pharmaceuticals industry. While PAHC belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health. PAHC scores decently on growth, while it is valued quite cheap. This could make an interesting combination. These ratings would make PAHC suitable for value investing!
1. Profitability
1.1 Basic Checks
In the past year PAHC was profitable.
In the past year PAHC had a positive cash flow from operations.
In the past 5 years PAHC has always been profitable.
Each year in the past 5 years PAHC had a positive operating cash flow.
1.2 Ratios
With an excellent Return On Assets value of 3.55%, PAHC belongs to the best of the industry, outperforming 86.46% of the companies in the same industry.
With an excellent Return On Equity value of 16.89%, PAHC belongs to the best of the industry, outperforming 90.63% of the companies in the same industry.
The Return On Invested Capital of PAHC (10.17%) is better than 87.50% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for PAHC is significantly below the industry average of 15.37%.
The 3 year average ROIC (8.29%) for PAHC is below the current ROIC(10.17%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.55% | ||
| ROE | 16.89% | ||
| ROIC | 10.17% |
ROA(3y)2.38%
ROA(5y)3.78%
ROE(3y)9.79%
ROE(5y)14.19%
ROIC(3y)8.29%
ROIC(5y)8.41%
1.3 Margins
PAHC's Profit Margin of 3.72% is amongst the best of the industry. PAHC outperforms 82.81% of its industry peers.
In the last couple of years the Profit Margin of PAHC has declined.
PAHC's Operating Margin of 10.60% is amongst the best of the industry. PAHC outperforms 83.33% of its industry peers.
In the last couple of years the Operating Margin of PAHC has grown nicely.
Looking at the Gross Margin, with a value of 31.59%, PAHC is in line with its industry, outperforming 57.81% of the companies in the same industry.
PAHC's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 10.6% | ||
| PM (TTM) | 3.72% | ||
| GM | 31.59% |
OM growth 3Y8.12%
OM growth 5Y4.74%
PM growth 3Y-10.66%
PM growth 5Y-2.37%
GM growth 3Y1.41%
GM growth 5Y-0.32%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so PAHC is still creating some value.
Compared to 1 year ago, PAHC has about the same amount of shares outstanding.
PAHC has about the same amout of shares outstanding than it did 5 years ago.
The debt/assets ratio for PAHC is higher compared to a year ago.
2.2 Solvency
An Altman-Z score of 3.01 indicates that PAHC is not in any danger for bankruptcy at the moment.
PAHC has a better Altman-Z score (3.01) than 69.79% of its industry peers.
The Debt to FCF ratio of PAHC is 17.18, which is on the high side as it means it would take PAHC, 17.18 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 17.18, PAHC is in the better half of the industry, outperforming 76.56% of the companies in the same industry.
A Debt/Equity ratio of 2.46 is on the high side and indicates that PAHC has dependencies on debt financing.
PAHC has a Debt to Equity ratio of 2.46. This is in the lower half of the industry: PAHC underperforms 79.17% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.46 | ||
| Debt/FCF | 17.18 | ||
| Altman-Z | 3.01 |
ROIC/WACC1.19
WACC8.54%
2.3 Liquidity
A Current Ratio of 2.76 indicates that PAHC has no problem at all paying its short term obligations.
The Current ratio of PAHC (2.76) is comparable to the rest of the industry.
PAHC has a Quick Ratio of 1.25. This is a normal value and indicates that PAHC is financially healthy and should not expect problems in meeting its short term obligations.
With a Quick ratio value of 1.25, PAHC is not doing good in the industry: 68.23% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.76 | ||
| Quick Ratio | 1.25 |
3. Growth
3.1 Past
PAHC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 76.43%, which is quite impressive.
The Earnings Per Share has been growing by 14.12% on average over the past years. This is quite good.
Looking at the last year, PAHC shows a very strong growth in Revenue. The Revenue has grown by 27.37%.
The Revenue has been growing by 10.12% on average over the past years. This is quite good.
EPS 1Y (TTM)76.43%
EPS 3Y19.98%
EPS 5Y14.12%
EPS Q2Q%108.57%
Revenue 1Y (TTM)27.37%
Revenue growth 3Y11.21%
Revenue growth 5Y10.12%
Sales Q2Q%39.74%
3.2 Future
Based on estimates for the next years, PAHC will show a quite strong growth in Earnings Per Share. The EPS will grow by 16.62% on average per year.
PAHC is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -2.45% yearly.
EPS Next Y28.48%
EPS Next 2Y19.22%
EPS Next 3Y16.62%
EPS Next 5YN/A
Revenue Next Year14.11%
Revenue Next 2Y8.5%
Revenue Next 3Y6.54%
Revenue Next 5Y-2.45%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 17.72 indicates a rather expensive valuation of PAHC.
82.81% of the companies in the same industry are more expensive than PAHC, based on the Price/Earnings ratio.
When comparing the Price/Earnings ratio of PAHC to the average of the S&P500 Index (26.06), we can say PAHC is valued slightly cheaper.
With a Price/Forward Earnings ratio of 14.73, PAHC is valued correctly.
PAHC's Price/Forward Earnings ratio is rather cheap when compared to the industry. PAHC is cheaper than 82.81% of the companies in the same industry.
PAHC is valuated cheaply when we compare the Price/Forward Earnings ratio to 32.73, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 17.72 | ||
| Fwd PE | 14.73 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, PAHC is valued cheaper than 83.33% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, PAHC is valued a bit cheaper than 78.65% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 42.4 | ||
| EV/EBITDA | 13.15 |
4.3 Compensation for Growth
PAHC's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The excellent profitability rating of PAHC may justify a higher PE ratio.
A more expensive valuation may be justified as PAHC's earnings are expected to grow with 16.62% in the coming years.
PEG (NY)0.62
PEG (5Y)1.26
EPS Next 2Y19.22%
EPS Next 3Y16.62%
5. Dividend
5.1 Amount
PAHC has a Yearly Dividend Yield of 1.12%. Purely for dividend investing, there may be better candidates out there.
PAHC's Dividend Yield is rather good when compared to the industry average which is at 6.99. PAHC pays more dividend than 90.63% of the companies in the same industry.
Compared to an average S&P500 Dividend Yield of 2.37, PAHC's dividend is way lower than the S&P500 average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.12% |
5.2 History
The dividend of PAHC has a limited annual growth rate of 0.02%.
PAHC has been paying a dividend for at least 10 years, so it has a reliable track record.
PAHC has not decreased its dividend for at least 10 years, so it has a reliable track record of non decreasing dividend.
Dividend Growth(5Y)0.02%
Div Incr Years0
Div Non Decr Years10
5.3 Sustainability
40.30% of the earnings are spent on dividend by PAHC. This is a bit on the high side, but may be sustainable.
The dividend of PAHC is growing, but earnings are growing more, so the dividend growth is sustainable.
DP40.3%
EPS Next 2Y19.22%
EPS Next 3Y16.62%
43.76
+0.72 (+1.67%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners105.31%
Inst Owner Change1.83%
Ins Owners0.65%
Ins Owner Change31.32%
Market Cap1.77B
Revenue(TTM)1.30B
Net Income(TTM)48.26M
Analysts48.89
Price Target33.32 (-23.86%)
Short Float %4.78%
Short Ratio3.03
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.12% |
Yearly Dividend0.48
Dividend Growth(5Y)0.02%
DP40.3%
Div Incr Years0
Div Non Decr Years10
Ex-Date
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)13.12%
Min EPS beat(2)7.47%
Max EPS beat(2)18.78%
EPS beat(4)4
Avg EPS beat(4)22.43%
Min EPS beat(4)7.47%
Max EPS beat(4)38.92%
EPS beat(8)7
Avg EPS beat(8)11.31%
EPS beat(12)8
Avg EPS beat(12)4.99%
EPS beat(16)9
Avg EPS beat(16)0.79%
Revenue beat(2)1
Avg Revenue beat(2)-0.37%
Min Revenue beat(2)-3.24%
Max Revenue beat(2)2.5%
Revenue beat(4)2
Avg Revenue beat(4)0.88%
Min Revenue beat(4)-3.24%
Max Revenue beat(4)4.46%
Revenue beat(8)5
Avg Revenue beat(8)0.17%
Revenue beat(12)6
Avg Revenue beat(12)-0.35%
Revenue beat(16)10
Avg Revenue beat(16)0.68%
PT rev (1m)0%
PT rev (3m)42.03%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-7.09%
EPS NY rev (1m)0%
EPS NY rev (3m)12.82%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.88%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 17.72 | ||
| Fwd PE | 14.73 | ||
| P/S | 1.37 | ||
| P/FCF | 42.4 | ||
| P/OCF | 22.14 | ||
| P/B | 6.21 | ||
| P/tB | 9.36 | ||
| EV/EBITDA | 13.15 |
EPS(TTM)2.47
EY5.64%
EPS(NY)2.97
Fwd EY6.79%
FCF(TTM)1.03
FCFY2.36%
OCF(TTM)1.98
OCFY4.52%
SpS31.98
BVpS7.05
TBVpS4.68
PEG (NY)0.62
PEG (5Y)1.26
Graham Number19.79
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.55% | ||
| ROE | 16.89% | ||
| ROCE | 12.87% | ||
| ROIC | 10.17% | ||
| ROICexc | 10.96% | ||
| ROICexgc | 12.13% | ||
| OM | 10.6% | ||
| PM (TTM) | 3.72% | ||
| GM | 31.59% | ||
| FCFM | 3.23% |
ROA(3y)2.38%
ROA(5y)3.78%
ROE(3y)9.79%
ROE(5y)14.19%
ROIC(3y)8.29%
ROIC(5y)8.41%
ROICexc(3y)9.26%
ROICexc(5y)9.5%
ROICexgc(3y)10.65%
ROICexgc(5y)11.26%
ROCE(3y)10.49%
ROCE(5y)10.64%
ROICexgc growth 3Y1.17%
ROICexgc growth 5Y-1.23%
ROICexc growth 3Y4.48%
ROICexc growth 5Y1.99%
OM growth 3Y8.12%
OM growth 5Y4.74%
PM growth 3Y-10.66%
PM growth 5Y-2.37%
GM growth 3Y1.41%
GM growth 5Y-0.32%
F-Score5
Asset Turnover0.95
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.46 | ||
| Debt/FCF | 17.18 | ||
| Debt/EBITDA | 3.84 | ||
| Cap/Depr | 83.97% | ||
| Cap/Sales | 2.95% | ||
| Interest Coverage | 4.28 | ||
| Cash Conversion | 43.79% | ||
| Profit Quality | 86.67% | ||
| Current Ratio | 2.76 | ||
| Quick Ratio | 1.25 | ||
| Altman-Z | 3.01 |
F-Score5
WACC8.54%
ROIC/WACC1.19
Cap/Depr(3y)116.74%
Cap/Depr(5y)111.08%
Cap/Sales(3y)4.1%
Cap/Sales(5y)3.95%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)76.43%
EPS 3Y19.98%
EPS 5Y14.12%
EPS Q2Q%108.57%
EPS Next Y28.48%
EPS Next 2Y19.22%
EPS Next 3Y16.62%
EPS Next 5YN/A
Revenue 1Y (TTM)27.37%
Revenue growth 3Y11.21%
Revenue growth 5Y10.12%
Sales Q2Q%39.74%
Revenue Next Year14.11%
Revenue Next 2Y8.5%
Revenue Next 3Y6.54%
Revenue Next 5Y-2.45%
EBIT growth 1Y114.01%
EBIT growth 3Y20.25%
EBIT growth 5Y15.34%
EBIT Next Year68.04%
EBIT Next 3Y23.72%
EBIT Next 5Y2.18%
FCF growth 1Y-9.76%
FCF growth 3YN/A
FCF growth 5Y10.58%
OCF growth 1Y-8.53%
OCF growth 3Y36.29%
OCF growth 5Y6.19%
PHIBRO ANIMAL HEALTH CORP-A / PAHC FAQ
Can you provide the ChartMill fundamental rating for PHIBRO ANIMAL HEALTH CORP-A?
ChartMill assigns a fundamental rating of 6 / 10 to PAHC.
Can you provide the valuation status for PHIBRO ANIMAL HEALTH CORP-A?
ChartMill assigns a valuation rating of 7 / 10 to PHIBRO ANIMAL HEALTH CORP-A (PAHC). This can be considered as Undervalued.
What is the profitability of PAHC stock?
PHIBRO ANIMAL HEALTH CORP-A (PAHC) has a profitability rating of 8 / 10.
How financially healthy is PHIBRO ANIMAL HEALTH CORP-A?
The financial health rating of PHIBRO ANIMAL HEALTH CORP-A (PAHC) is 5 / 10.
Can you provide the expected EPS growth for PAHC stock?
The Earnings per Share (EPS) of PHIBRO ANIMAL HEALTH CORP-A (PAHC) is expected to grow by 28.48% in the next year.